The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Checkmate577: nivolumab in EC/GEJC
Ronan J. Kelly, MD, MBA, Baylor Scott & White Health, Dallas, Texas, discusses the expanded efficacy and safety analysis from Checkmate 577; a Phase III study of adjuvant nivolumab in patients with esophageal and gastroesophageal junction cancer (EC/GEJC) who have residual pathologic disease after receiving neoadjuvant chemoradiotherapy (NCT02743494). Adjuvant nivolumab demonstrated clinically significant efficacy and safety profiles; the primary endpoint of disease-free survival (DFS) was met, with DFS doubling and being maintained across subgroups, the risk of recurrence or death was decreased by 30%, median distant metastasis-free survival increased by 11 months, distant and loco-regional recurrences were reduced in frequency, progression-free survival 2 (PFS2) was improved, treatment was well-tolerated and safe. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
